Holdings
Birchview Capital, LP
As of Sep 30, 2026, Birchview Capital, LP reported 65 positions worth US$150M. Largest: KLA Corporation, Bristol-Myers Squibb Company and Lam Research Corporation. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| KLA Corporation | 167K | US$32.5M | −11,533 | Sep 30, 2026 |
| Bristol-Myers Squibb Company | 224K | US$14M | −72,998 | Sep 30, 2026 |
| Lam Research Corporation | 30,000 | US$9.86M | −5,000 | Sep 30, 2026 |
| Corcept Therapeutics Incorporated | 55,200 | US$6.36M | −2,000 | Sep 30, 2026 |
| Ovintiv Inc. (de) | 108K | US$6.22M | no change | Sep 30, 2026 |
| Ultragenyx Pharmaceutical Inc. | 374K | US$5.62M | new | Sep 30, 2026 |
| Solid Biosciences Inc. | 716K | US$5.18M | +49,759 | Sep 30, 2026 |
| Protagonist Therapeutics, Inc. | 35,000 | US$4.93M | −18 | Sep 30, 2026 |
| Halozyme Therapeutics, Inc. | 33,351 | US$3.68M | +100 | Sep 30, 2026 |
| Stoke Therapeutics, Inc. | 138K | US$3.59M | −40,110 | Sep 30, 2026 |